Monoclonal Antibody Therapy in Parkinson’s Disease – The End?

Related Articles:

• The road ahead: 2022 January 20, 2022 # # # # The first post at the start of each year on the SoPD website tries to provide an overview of where things are in the search for ‘disease modifying’ therapies for Parkinson’s.  It is an exercise in managing expectations as well as discussing what research events are scheduled for the next year so that we can keep…
• The Llama-nation of LRRK2 April 8, 2022 # # # # Antibodies are tiny y-shaped markers used by the immune system to label foreign agents within the body. Once bound to something, antibodies can alert immune cells to come and remove the object. Antibodies can also inhibit the object from doing anything nasty, like infecting or damaging a cell. Between species, different types of antibodies have been…
• Monoclonal Antibody Therapy in Parkinson's Disease - The End? August 3, 2022 N Engl J Med. 2022 Aug 4;387(5):466-467. doi: 10.1056/NEJMe2207681.NO ABSTRACTPMID:35921458 | DOI:10.1056/NEJMe2207681
• Monoclonal Antibody Therapy in Parkinson's Disease - The End? August 3, 2022 N Engl J Med. 2022 Aug 4;387(5):466-467. doi: 10.1056/NEJMe2207681.NO ABSTRACTPMID:35921458 | DOI:10.1056/NEJMe2207681
• Monoclonal Antibody Therapy in Parkinson's Disease - The End? August 3, 2022 N Engl J Med. 2022 Aug 4;387(5):466-467. doi: 10.1056/NEJMe2207681.NO ABSTRACTPMID:35921458 | DOI:10.1056/NEJMe2207681
• Monoclonal Antibody Therapy in Parkinson's Disease - The End? August 3, 2022 N Engl J Med. 2022 Aug 4;387(5):466-467. doi: 10.1056/NEJMe2207681.NO ABSTRACTPMID:35921458 | DOI:10.1056/NEJMe2207681
• The road ahead: 2021 January 25, 2021 # # # # At the start of each year, it is a useful practise to layout what is planned over the next 12 months. The events that are scheduled for the year to come, so that we can keep an eye out for them. Obviously, where 2021 will end actually is unpredictable, but an outline of what is scheduled…
• Does immunotherapy need therapy? June 12, 2021 # # # # Over the last decade, a large number of clinical trials involving immunotherapy have been conducted in the field of Alzheimer’s research. The overall success rate of these studies has not been encouraging. Immunotherapy involves artificially boosting the immune system so that it targets of particular pathogen – like a rogue protein in the case of Alzheimer’s…
• Shining a light on Parkinson’s November 7, 2019   NOTE: The information in today’s post should not be considered an endorsement of PhotoPharmics or the treatment they are proposing. The author of this blog has had no communication with the company. The information in this post is provided because the author has been asked by readers to discuss it. In October 2018, at the annual International Movement Disorders…
• Novel method for screening functional antibody with comprehensive analysis of its immunoliposome February 26, 2021 Sci Rep. 2021 Feb 25;11(1):4625. doi: 10.1038/s41598-021-84043-w.ABSTRACTDevelopment of monoclonal antibody is critical for targeted drug delivery because its characteristics determine improved therapeutic efficacy and reduced side-effect. Antibody therapeutics target surface molecules; hence, internalization is desired for drug delivery. As an antibody-drug conjugate, a critical parameter is drug-to-antibody ratio wherein the quantity of drugs attached to the antibody influences the antibody…
• Novel method for screening functional antibody with comprehensive analysis of its immunoliposome February 26, 2021 Sci Rep. 2021 Feb 25;11(1):4625. doi: 10.1038/s41598-021-84043-w.ABSTRACTDevelopment of monoclonal antibody is critical for targeted drug delivery because its characteristics determine improved therapeutic efficacy and reduced side-effect. Antibody therapeutics target surface molecules; hence, internalization is desired for drug delivery. As an antibody-drug conjugate, a critical parameter is drug-to-antibody ratio wherein the quantity of drugs attached to the antibody influences the antibody…
• Novel method for screening functional antibody with comprehensive analysis of its immunoliposome February 26, 2021 Sci Rep. 2021 Feb 25;11(1):4625. doi: 10.1038/s41598-021-84043-w.ABSTRACTDevelopment of monoclonal antibody is critical for targeted drug delivery because its characteristics determine improved therapeutic efficacy and reduced side-effect. Antibody therapeutics target surface molecules; hence, internalization is desired for drug delivery. As an antibody-drug conjugate, a critical parameter is drug-to-antibody ratio wherein the quantity of drugs attached to the antibody influences the antibody…
• Novel method for screening functional antibody with comprehensive analysis of its immunoliposome February 26, 2021 Sci Rep. 2021 Feb 25;11(1):4625. doi: 10.1038/s41598-021-84043-w.ABSTRACTDevelopment of monoclonal antibody is critical for targeted drug delivery because its characteristics determine improved therapeutic efficacy and reduced side-effect. Antibody therapeutics target surface molecules; hence, internalization is desired for drug delivery. As an antibody-drug conjugate, a critical parameter is drug-to-antibody ratio wherein the quantity of drugs attached to the antibody influences the antibody…
• Novel method for screening functional antibody with comprehensive analysis of its immunoliposome February 26, 2021 Sci Rep. 2021 Feb 25;11(1):4625. doi: 10.1038/s41598-021-84043-w.ABSTRACTDevelopment of monoclonal antibody is critical for targeted drug delivery because its characteristics determine improved therapeutic efficacy and reduced side-effect. Antibody therapeutics target surface molecules; hence, internalization is desired for drug delivery. As an antibody-drug conjugate, a critical parameter is drug-to-antibody ratio wherein the quantity of drugs attached to the antibody influences the antibody…
• Novel method for screening functional antibody with comprehensive analysis of its immunoliposome February 26, 2021 Sci Rep. 2021 Feb 25;11(1):4625. doi: 10.1038/s41598-021-84043-w.ABSTRACTDevelopment of monoclonal antibody is critical for targeted drug delivery because its characteristics determine improved therapeutic efficacy and reduced side-effect. Antibody therapeutics target surface molecules; hence, internalization is desired for drug delivery. As an antibody-drug conjugate, a critical parameter is drug-to-antibody ratio wherein the quantity of drugs attached to the antibody influences the antibody…
• The road ahead: 2020 January 5, 2020 Here at the SoPD, we are primarily interested in disease modification for Parkinson’s. While there is a great deal of interesting research exploring the causes of the condition, novel symptomatic therapies, and other aspects of Parkinson’s, my focus is generally on the science seeking to slow, stop or reverse the condition. At the start of each year, it is a…
• Trial of Cinpanemab in Early Parkinson's Disease August 3, 2022 N Engl J Med. 2022 Aug 4;387(5):408-420. doi: 10.1056/NEJMoa2203395.ABSTRACTBACKGROUND: Aggregated α-synuclein plays an important role in Parkinson's disease pathogenesis. Cinpanemab, a human-derived monoclonal antibody that binds to α-synuclein, is being evaluated as a disease-modifying treatment for Parkinson's disease.METHODS: In a 52-week, multicenter, double-blind, phase 2 trial, we randomly assigned, in a 2:1:2:2 ratio, participants with early Parkinson's disease to receive…
• Trial of Cinpanemab in Early Parkinson's Disease August 3, 2022 N Engl J Med. 2022 Aug 4;387(5):408-420. doi: 10.1056/NEJMoa2203395.ABSTRACTBACKGROUND: Aggregated α-synuclein plays an important role in Parkinson's disease pathogenesis. Cinpanemab, a human-derived monoclonal antibody that binds to α-synuclein, is being evaluated as a disease-modifying treatment for Parkinson's disease.METHODS: In a 52-week, multicenter, double-blind, phase 2 trial, we randomly assigned, in a 2:1:2:2 ratio, participants with early Parkinson's disease to receive…
• Trial of Cinpanemab in Early Parkinson's Disease August 3, 2022 N Engl J Med. 2022 Aug 4;387(5):408-420. doi: 10.1056/NEJMoa2203395.ABSTRACTBACKGROUND: Aggregated α-synuclein plays an important role in Parkinson's disease pathogenesis. Cinpanemab, a human-derived monoclonal antibody that binds to α-synuclein, is being evaluated as a disease-modifying treatment for Parkinson's disease.METHODS: In a 52-week, multicenter, double-blind, phase 2 trial, we randomly assigned, in a 2:1:2:2 ratio, participants with early Parkinson's disease to receive…
• Trial of Cinpanemab in Early Parkinson's Disease August 3, 2022 N Engl J Med. 2022 Aug 4;387(5):408-420. doi: 10.1056/NEJMoa2203395.ABSTRACTBACKGROUND: Aggregated α-synuclein plays an important role in Parkinson's disease pathogenesis. Cinpanemab, a human-derived monoclonal antibody that binds to α-synuclein, is being evaluated as a disease-modifying treatment for Parkinson's disease.METHODS: In a 52-week, multicenter, double-blind, phase 2 trial, we randomly assigned, in a 2:1:2:2 ratio, participants with early Parkinson's disease to receive…
• Monoclonal Antibodies as Neurological Therapeutics. February 4, 2021 Related ArticlesMonoclonal Antibodies as Neurological Therapeutics. Pharmaceuticals (Basel). 2021 Jan 26;14(2): Authors: Gklinos P, Papadopoulou M, Stanulovic V, Mitsikostas DD, Papadopoulos D Abstract Over the last 30 years the role of monoclonal antibodies in therapeutics has increased enormously, revolutionizing treatment in most medical specialties, including neurology. Monoclonal antibodies are key therapeutic agents for several neurological conditions with diverse pathophysiological mechanisms,…
• Is a vaccine for Parkinson’s disease possible? November 3, 2020 As the world awaits an effective vaccine for SARS-CoV2 (the virus that causes COVID-19), vaccines and vaccination are at the front and center of the news and in our minds. A vaccine is a substance that is introduced into the body in order to stimulate the immune system to provide protection against a particular disease. Did you know that many…